Beta Drugs マネジメント
マネジメント 基準チェック /44
Beta Drugsの CEO はRahul Batraで、 Jan2021年に任命され、 の在任期間は 3.83年です。 の年間総報酬は₹ 12.10Mで、 100%給与と0%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.41%を直接所有しており、その価値は₹ 86.99M 。経営陣と取締役会の平均在任期間はそれぞれ3.8年と7.3年です。
主要情報
Rahul Batra
最高経営責任者
₹12.1m
報酬総額
CEO給与比率 | 100.0% |
CEO在任期間 | 3.8yrs |
CEOの所有権 | 0.4% |
経営陣の平均在職期間 | 3.8yrs |
取締役会の平均在任期間 | 7.3yrs |
経営陣の近況
Recent updates
Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge
Nov 08Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Aug 30Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%
Aug 30Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%
Dec 23Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Dec 11These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Jul 29Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching
Jun 17Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today
Feb 21Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
Dec 20With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting
Nov 21These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Sep 02Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
May 20Is Beta Drugs (NSE:BETA) A Risky Investment?
Jan 29Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Dec 25Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)
Nov 20CEO報酬分析
日付 | 総報酬 | 給与 | 会社業績 |
---|---|---|---|
Sep 30 2024 | n/a | n/a | ₹410m |
Jun 30 2024 | n/a | n/a | ₹387m |
Mar 31 2024 | ₹12m | ₹12m | ₹364m |
Dec 31 2023 | n/a | n/a | ₹356m |
Sep 30 2023 | n/a | n/a | ₹348m |
Jun 30 2023 | n/a | n/a | ₹327m |
Mar 31 2023 | ₹12m | n/a | ₹307m |
Dec 31 2022 | n/a | n/a | ₹298m |
Sep 30 2022 | n/a | n/a | ₹289m |
Jun 30 2022 | n/a | n/a | ₹269m |
Mar 31 2022 | ₹8m | ₹8m | ₹248m |
Dec 31 2021 | n/a | n/a | ₹216m |
Sep 30 2021 | n/a | n/a | ₹183m |
Jun 30 2021 | n/a | n/a | ₹150m |
Mar 31 2021 | ₹6m | ₹6m | ₹117m |
Dec 31 2020 | n/a | n/a | ₹106m |
Sep 30 2020 | n/a | n/a | ₹95m |
Jun 30 2020 | n/a | n/a | ₹94m |
Mar 31 2020 | ₹5m | ₹5m | ₹94m |
Sep 30 2019 | n/a | n/a | ₹97m |
Jun 30 2019 | n/a | n/a | ₹89m |
Mar 31 2019 | ₹1m | ₹1m | ₹80m |
報酬と市場: Rahulの 総報酬 ($USD 143.42K ) は、 Indian市場 ($USD 179.34K ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Rahulの報酬は、過去 1 年間の会社の業績と一致しています。
CEO(最高経営責任者
Rahul Batra (41 yo)
3.8yrs
在職期間
₹12,100,000
報酬
Mr. Rahul Batra serves as the Chairman & Managing Director of Beta Drugs Limited since January 27, 2021. He had been Whole Time Director of Beta Drugs Limited since August 1, 2014 until January 27, 2021. H...
リーダーシップ・チーム
名称 | ポジション | 在職期間 | 報酬 | 所有権 |
---|---|---|---|---|
Chairman & MD | 3.8yrs | ₹12.10m | 0.41% ₹ 85.7m | |
Joint MD & Whole Time Director | 3.8yrs | ₹12.10m | 0.35% ₹ 71.8m | |
Chief Financial Officer | 3.7yrs | ₹3.10m | データなし | |
Company Secretary & Compliance Officer | 7.3yrs | ₹911.55k | データなし | |
VP of Sales & Marketing and Whole Time Director | 5.7yrs | ₹5.12m | データなし | |
Whole Time Director | no data | ₹1.19m | データなし | |
Vice President of Technical | no data | データなし | データなし |
3.8yrs
平均在職期間
40.5yo
平均年齢
経験豊富な経営陣: BETAの経営陣は 経験豊富 であると考えられます ( 3.8年の平均在職年数)。
取締役
名称 | ポジション | 在職期間 | 報酬 | 所有権 |
---|---|---|---|---|
Chairman & MD | 10.3yrs | ₹12.10m | 0.41% ₹ 85.7m | |
Joint MD & Whole Time Director | 10.3yrs | ₹12.10m | 0.35% ₹ 71.8m | |
VP of Sales & Marketing and Whole Time Director | 2.8yrs | ₹5.12m | データなし | |
Whole Time Director | 5.3yrs | ₹1.19m | データなし | |
Independent Director | 7.3yrs | データなし | データなし | |
Independent Director | 7.3yrs | データなし | データなし |
7.3yrs
平均在職期間
48yo
平均年齢
経験豊富なボード: BETAの 取締役会 は 経験豊富 であると考えられます ( 7.3年の平均在任期間)。